Elements for a public summary

VI.2.1 Overview of disease epidemiology

Olmesartan+hydrochlorothiazid fixed dose combinations are indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil alone.

Essential hypertension¹

Worldwide, it is estimated that 1 billion people are hypertensive, accounting for an estimated 7.1 million deaths per year. It is becoming an increasingly common problem because of increased longevity and the prevalence of contributing factors such as obesity, physical inactivity, and unhealthy diet. The prevalence in many developing countries, particularly urban societies, is already as high as those seen in developed countries.

The prevalence of essential hypertension in the US was estimated to be 65 million people in 2000, compared with 50 million people in 1990. The incidence increases with age in people of all ancestries and both sexes. Prevalence is higher in men than in women before 60 years of age, but equal after this age. The lifetime risk is 90% for men and women who were normotensive at 55 years of age and survive to 80 years.

VI.2.2 Summary of treatment benefits

The marketing authorizations for olmesartan+hydrochlorothiazide are for generic medicinal products. Their treatment benefits are thought to be similar to the ones proposed by the innovator..

Olmesartan is a nonpeptide angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT 1 receptors in tissues such as vascular smooth muscle in blood vessel walls and the adrenal gland. Olmesartan, by blocking the binding of angiotensin II to the AT 1 receptors, promotes vasodilation and decreases the effects of aldosterone. The negative feedback regulation of angiotensin II on renin secretion is also inhibited, resulting in a rise in plasma renin concentrations and a consequent rise in angiotensin II plasma concentrations. However, these effects do not counteract the blood pressure—lowering effect that occurs.

Hydrochlorothiazide is a diuretic that directly increases excretion of sodium and chloride and indirectly reduces plasma volume. The mechanism of its antihypertensive effect is not known.

VI.2.3 Unknowns relating to treatment benefits

There are no data available on use in paediatric patients during breastfeeding or in patients with severe hepatic impairment.

¹ http://bestpractice.bmj.com/best-practice/monograph/26/basics/epidemiology.html

VI.2.4 Summary of safety concerns

Important identified risks

Risk	What is known	Preventability
Drug Use During Pregnancy (Exposure during the 2 nd and 3 rd trimester of pregnancy)	Drugs taken by a pregnant woman reach the fetus primarily by crossing the placenta, the same route taken by oxygen and nutrients, which are needed for the fetus's growth and development. Drugs that a pregnant woman takes during pregnancy can affect the fetus in several ways, for example, drugs that lower the mother's blood pressure may reduce blood flow to the placenta and thus reduce the supply of oxygen and nutrients to the fetus.	Do not take <invented name=""> if you are more than 3 months pregnant. (It is also better to avoid <invented name=""> in early pregnancy – see pregnancy section.) You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking this drug before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of this drug. Olmesartan medoxomil is not recommended in early pregnancy, and must not be taken when more than 3 months of pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. Pregnancy and breast-feeding Pregnancy You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking <invented name=""> before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of <invented name="">. <invented name=""> is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. Breast-feeding Tell your doctor if you are breast-feeding or about to start breast-feeding. <invented name=""> is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a</invented></invented></invented></invented></invented></invented>
Kidney impairment, low	Changes in kidney	baby, ask your doctor or pharmacist for advice before taking this medicine. Yes, by monitoring of biochemical laboratory
blood pressure and high potassium levels in case of co-	function, low blood pressure and high potassium levels have	tests. Do not take <invented name="">: if you have diabetes or impaired kidney</invented>
administration of 2 different drugs which affect renin- angiotensin-aldosteron	been reported in some individuals who were treated with another medicine which affect	function and you are treated with a blood pressure lowering medicine containing

system	renin-angiotensin-	aliskiren
(Renal dysfunction, hypotension and hyperkalaemia as consequence of dual RAAS* blockade)	aldosteron system.	Before you take the tablets, tell your doctor if you have any of the following health problems: - if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. - aliskiren Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading "Do not take <invented name="">"</invented>
		Other medicines and <invented name=""> Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, tell your doctor or pharmacist about any of the following: - Your doctor may need to change your dose and/or to take other precautions: - If you are taking an ACE-inhibitor or aliskiren (see also information under the headings "Do not take <invented name="">" and "Warnings and precautions")</invented></invented>
disease with Celiac-like symptoms (Sprue-like enteropathy)	This condition was reported in very rare cases. Symptoms include severe, chronic diarrhea, malnutrition and substantial weight loss. It is possibly caused by a delayed hypersensitivity reaction. If you develop these symptoms during treatment with olmesartan, your doctor should exclude other causes.	Contact your doctor if you experience diarrhoea that is severe, persistent and causes substantial weight loss. Your doctor may evaluate your symptoms and decide on how to continue your blood pressure medication. In case you experience severe, chronic diarrhea and weight loss you should consult with doctor. If disease with Celiac-like symptoms (Sprue-like enteropathy) is confirmed, treatment with olmesartan should be stopped.
Sudden kidney injury (Acute renal impairment)	Acute kidney failure occurs when your kidneys suddenly become unable to filter waste products from your blood. When your kidneys lose their	Your doctor may check your kidney function at regular intervals. Tell your doctor if you have any kidney problems.

filtering ability, dangerous levels of wastes may accumulate, and your blood's chemical makeup may get out of balance.

Acute kidney failure also called acute renal failure or acute kidney injury — develops rapidly over a few hours or a few days. Acute kidney failure is most common in people who are already hospitalized, particularly in critically ill people who need intensive care. Acute kidney failure can be fatal and requires intensive treatment. However, acute kidney failure may be reversible. If you're otherwise in good health, you may recover normal or nearly normal kidney function.

Do not take <Invented name>- if you have impaired kidney function.

- if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren

Before you take the tablets, **tell your doctor** if you have any of the following health problems:

- if you are taking any of the following medicines used to treat high blood pressure:
 - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
 - aliskiren

In patients with mild to moderate kidney disease, your dose will not be higher than 20 mg once a day.

Acute kidney failure is rare side effect of this medicine.

Impaired kidney function is rare side effect of olmesartan medoxomil component of this medicine.

Abnormally low pressure of the blood called also low blood pressure (Acute hypotension)	As with any medicine which reduces blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances of the heart or brain could lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.	Other blood pressure lowering medicines (anti-hypertensives), as the effect of this drug can be increased. Your doctor may need to change your dose and/or to take other precautions. If you are over 65 years of age and your doctor decides to increase your dose of olmesartan medoxomil to 40 mg daily, then you need to have your blood pressure regularly checked by your doctor to make sure that your blood pressure does not become too low. Your doctor may check your blood pressure at regular intervals. Tell your doctor if you have any of the following health problems: if you are taking any of the following medicines used to treat high blood pressure: an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. aliskiren
Change of the levels of certain chemicals (Electrolyte imbalance)	This drug may change the levels of certain chemicals in your blood called electrolytes. Your doctor will probably want to do a blood test from time to time to check these. Very rare side effects (may affect up to 1 in 10,000 people): Electrolyte disturbance leading to an abnormally depleted level of chloride in the blood (hypochloraemic alkalosis), blockage in the gut (paralytic ileus).	Signs of electrolyte changes are: thirst, dryness of the mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, sluggish, tired, sleepy or restless, nausea, vomiting, less need to pass water, a rapid heart rate. Tell your doctor if you notice these symptoms. Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. Very rare side effect of hydrochlorothiazide component of this medicine is Electrolyte disturbance leading to an abnormally depleted level of chloride in the blood (hypochloraemic alkalosis).
Allergic reactions (Hypersensitivity reactions)	Allergic (hypersensitivity) reactions to a drug are relatively uncommon. In contrast to other types of adverse drug reactions, the number and severity of allergic reactions do not usually correlate with the amount of drug taken. For people who are allergic to a drug, even a small amount of the drug can trigger an allergic	Uncommon side effects of this drug can be quick allergic reactions that may affect the whole body and may cause breathing problems as well as a rapid fall of blood pressure that may even lead to fainting (anaphylactic reactions), vertigo, vomiting, weakness, feeling unwell, muscular pain, skin rash, allergic skin rash, itching, exanthema (skin eruption), skin lumps (wheals), angina (pain or uncomfortable feeling in the chest).

reaction. These reactions range from minor and simply annoying to severe and life threatening. Examples are rashes and itching; fever; constriction of the airways and wheezing; swelling of tissues (such as the voice box [larynx] and the opening between the vocal cords that closes to stop the flow of air to the lungs [glottis]), which impairs breathing; and a fall in blood pressure, sometimes to dangerously low levels.

Drug-drug interaction with lithium (a medicine used to treat mood swings and some types of depression)	The effect a drug has on a person may be different than expected because that drug interacts with another drug the person is taking (drug-drug interaction). The effects of drug interactions are usually unwanted and sometimes harmful. Interactions may increase or decrease the actions of one or more drugs, resulting in side effects or failed treatment.	You should tell your doctor or pharmacist if you take, have recently taken or might be taking any other medicines such as Lithium (a medicine used to treat mood swings and some types of depression) used at the same time as this drug may increase the toxicity of lithium. If you have to take lithium, your doctor will measure your lithium blood levels.
Drug-drug interaction with medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis (NSAID- Non-Steroidal Anti-Inflammatory).	The effect a drug has on a person may be different than expected because that drug interacts with another drug the person is taking (drug-drug interaction). The effects of drug interactions are usually unwanted and sometimes harmful. Interactions may increase or decrease the actions of one or more drugs, resulting in side effects or failed treatment.	You should tell your doctor or pharmacist if you take, have recently taken or might be taking any other medicines such as: Non-Steroidal Anti-Inflammatory (NSAIDs) medicines (medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis) used at the same time as this drug may increase the risk of kidney failure and the effect of this drug can be decreased by NSAIDs.
Increase in cholesterol and triglyceride levels	Cholesterol is a type of fat (lipid) in your blood. If you have too much fat in your blud can it starts to build up in your arteries. (Arteries are the blood vessels that carry blood away from the heart.) This is called hardening of the arteries, or atherosclerosis. It is the starting point for some heart and blood flow problems. The buildup can narrow the arteries and make it harder for blood to flow through them. The buildup can also lead to dangerous blood clots and inflammation that can cause heart attacks and strokes.	Some changes in blood test results have been recorded as very common side effects for hydochlorothiazide component of this medicine and include increase in increase in blood fat. Your doctor will know about these from a blood test and will tell you if you need to do anything.
Impaired flow of bile	With cholestasis, the flow	Do not take this medicine if you suffer from

(Cholestasis)	of bile (the digestive fluid produced by the liver) is impaired at some point between the liver cells (which produce bile) and the duodenum (the first segment of the small intestine). When bile flow is stopped, the pigment bilirubin (a waste product formed when old or damaged red blood cells are broken down) escapes into the bloodstream and accumulates. Normally, bilirubin binds with bile in the liver, moves through the bile ducts into the digestive tract, and is eliminated from the body. Most bilirubin is eliminated in stool, but a small amount is eliminated in urine.	yellowing of the skin and eyes (jaundice) or problems with drainage of the bile from the gallbladder (biliary obstruction e.g. gallstones). Some changes in blood test results have been seen uncommonly and include increase in levels of liver function.
Exacerbation/activation of systemic lupus erythematosus	Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that has protean manifestations and follows a relapsing and remitting course.	Rare side effects which may affect up to 1 in 1,000 people can also be symptoms of lupus erythematosus (such as rash, joint pains and cold hands and fingers)
Impaired glucose tolerance	Impaired glucose tolerance means that blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis. With impaired glucose tolerance you face a much greater risk of developing diabetes and cardiovascular disease.	Common side effect which may affect up to 1 in 10 people can increase in blood sugar levels.

Important potential risks

Risk	What is known (Including reason why it is considered a potential risk)
Skeletal muscle destruction (Rhabdomyolysis)	There are no data suggesting causal relationship between olmesartan and rhabdomyolysis. Single cases of
(Knabuomyorysis)	rhabdomyolysis have been reported in temporal association with the intake of the group of medicine to which

Skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, or blistering and peeling of the top layer of skin (toxic epidermal necrolysis)	olmesartan belongs (angiotensin II receptor blockers). Rhabdomyolysis is potentially life threatening muscle damage and due to the seriousness of the condition and its potential public health impact, rhabdomyolysis is monitored to detect potential relationship between olmesartan use and rhabdomyolysis. The frequency of side effects cannot be estimated from available data. In case of early symptoms these serious skin disorders can be prevented.
(Severe cutaneous	
reactions)	
Near-sightedness and acute	Among uncommon side effects which may affect up to 1 in
glaucoma	100 people when on this drug is worsening of pre-existing
(Myopia and angle-closure	near sightedness.
glaucoma)	
Exposure during the 1 st	Drugs taken by a pregnant woman reach the fetus primarily
trimester of pregnancy	by crossing the placenta, the same route taken by oxygen and
	nutrients, which are needed for the fetus's growth and
	development. Drugs that a pregnant woman takes during
	pregnancy can affect the fetus in several ways, for example,
	drugs that lower the mother's blood pressure may reduce
	blood flow to the placenta and thus reduce the supply of
	oxygen and nutrients to the fetus.

^{*}RAAS - renin-angiotensin-aldosteron system.

Missing information

Risk	What is known
Use in children and adolescents (less than 18 years of age)	This product is not recommended in children and adolescents (less than 18 years of age) since safety of the product has not yet been established.
(Use in paediatric patients)	
The use in patients with severe renal impairment and in patients with a recent kidney transplant	Do not take <invented name=""> if you have severe kidney problems. There is no experience of the administration of this drug in patients with a recent kidney transplant or in patients with end-stage renal impairment, therefore use of this product is not recommended in patients with severe renal impairment.</invented>
Use during breast feeding	Tell your doctor if you are breast-feeding or about to start breast-feeding. This drug is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or

pharmacist for advice before taking this medicine.

VI.2.5 Summary of risk minimisation measures by safety concern

All medicines have a Summary of Product Characteristics (SmPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PL). The measures in these documents are known as routine risk minimisation measures.

This medicine has no additional risk minimisation measures.

VI.2.6 Planned post authorisation development plan

Not applicable. No postauthorisation studies are planned.

VI.2.7 Summary of changes to the Risk Management Plan over time

Not applicable, this is the first Risk management plan.